marked.bio

anti-CD73 antibody · antibody

oleclumab

2 active trials across 3 of our biomarkers, targeting CD73. Not approved for any biomarker on marked.bio yet.

Also known as MEDI9447.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 1 2 Phase 1/2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 1 Phase 1/2
MSI-H / dMMR 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of oleclumab.

  1. AstraZeneca 2

Trials

2 of 4 trials shown

  1. Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

    Active, not recruiting Phase 1/2 AstraZeneca Started 2018Primary completion 2021-05 NCT03381274

    oleclumabosimertinib FDA EUAZD4635

    …sed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFRm

    EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung

  2. A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

    Active, not recruiting Phase 1/2 AstraZeneca Started 2018Primary completion 2024-11 NCT03742102

    durvalumabcapivasertiboleclumabpaclitaxeltrastuzumab deruxtecan FDA EUdatopotamab deruxtecan

    …provide documentation of locally determined advanced/unresectable or metastatic TNBC with HER2 low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Triple Negative Breast Neoplasms